TPN10475 alleviates concanavalin A-induced autoimmune hepatitis by limiting T cell development and function through inhibition of PI3K-AKT pathway.

MLA

Wang, Chun, et al. “TPN10475 Alleviates Concanavalin A-Induced Autoimmune Hepatitis by Limiting T Cell Development and Function through Inhibition of PI3K-AKT Pathway.” International Immunopharmacology, vol. 125, no. Pt A, Dec. 2023, p. 111110. EBSCOhost, https://doi.org/10.1016/j.intimp.2023.111110.

APA

Wang, C., Han, M., Li, X., Lv, J., Zhuang, W., Xie, L., Liu, G., Saimaier, K., Han, S., Shi, C., Hua, Q., Zhang, R., Jiang, X., Wang, G., & Du, C. (2023). TPN10475 alleviates concanavalin A-induced autoimmune hepatitis by limiting T cell development and function through inhibition of PI3K-AKT pathway. International Immunopharmacology, 125(Pt A), 111110. https://doi.org/10.1016/j.intimp.2023.111110

Chicago

Wang, Chun, Mengyao Han, Xinhang Li, Jie Lv, Wei Zhuang, Ling Xie, Guangyu Liu, et al. 2023. “TPN10475 Alleviates Concanavalin A-Induced Autoimmune Hepatitis by Limiting T Cell Development and Function through Inhibition of PI3K-AKT Pathway.” International Immunopharmacology 125 (Pt A): 111110. doi:10.1016/j.intimp.2023.111110.